Summary
Global Markets Direct’s, ‘Ulcerative Colitis - Pipeline Review, H1 2016’, provides an overview of the Ulcerative Colitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
- The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects
- The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4D Pharma Plc
AbbVie Inc.
Advinus Therapeutics Ltd.
Ajinomoto Pharmaceuticals Co., Ltd.
Am-Pharma B.V.
Amgen Inc.
Arena Pharmaceuticals, Inc.
Atlantic Healthcare Plc
Avaxia Biologics, Inc.
BioAtla, LLC
Bionovis SA
Celgene Corporation
Cellceutix Corporation
ChemoCentryx, Inc.
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp.
Coherus BioSciences, Inc.
Cosmo Pharmaceuticals S.p.A
Dr. Falk Pharma GmbH
Effimune S.A.
Eli Lilly and Company
Enceladus Pharmaceuticals BV
enGene, Inc
Enterome Bioscience SA
Epirus Biopharmaceuticals, Inc.
Flexion Therapeutics, Inc.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
iCo Therapeutics Inc.
Idera Pharmaceuticals, Inc.
InDex Pharmaceuticals AB
Innovate Biopharmaceuticals, Inc.
INOXIA Lifesciences GmbH
Intas Pharmaceuticals Ltd.
Invion Limited
Johnson & Johnson
Kaken Pharmaceutical Co., Ltd.
Kymab Limited
Kyowa Hakko Kirin Co., Ltd.
LIPID THERAPEUTICS GmbH
Mabion SA
Medestea Research & Production S.p.A.
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
Oncobiologics, Inc.
Pfizer Inc.
Pluristem Therapeutics Inc.
ProtAb Ltd
Protagonist Therapeutics Inc.
Qu Biologics Inc.
Re-Pharm Limited
Rebiotix Inc.
Sandoz International GmbH
Seres Therapeutics, Inc.
Sigmoid Pharma Limited
Stelic Institute & Co., Inc.
sterna biologicals Gmbh & Co KG
Synergy Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Therapeutic Proteins International, LLC
Therapix Biosciences Ltd
Theravance Biopharma, Inc.
Tillotts Pharma AG
Trino Therapeutics Limited
Ventria Bioscience
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis - Overview 12
Pipeline Products for Ulcerative Colitis - Comparative Analysis 13
Ulcerative Colitis - Therapeutics under Development by Companies 14
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 21
Ulcerative Colitis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Ulcerative Colitis - Products under Development by Companies 26
Ulcerative Colitis - Products under Investigation by Universities/Institutes 34
Ulcerative Colitis - Companies Involved in Therapeutics Development 35
4D Pharma Plc 35
AbbVie Inc. 36
Advinus Therapeutics Ltd. 37
Ajinomoto Pharmaceuticals Co., Ltd. 38
Am-Pharma B.V. 39
Amgen Inc. 40
Arena Pharmaceuticals, Inc. 41
Atlantic Healthcare Plc 42
Avaxia Biologics, Inc. 43
BioAtla, LLC 44
Bionovis SA 45
Celgene Corporation 46
Cellceutix Corporation 47
ChemoCentryx, Inc. 48
ChironWells GmbH 49
Chong Kun Dang Pharmaceutical Corp. 50
Coherus BioSciences, Inc. 51
Cosmo Pharmaceuticals S.p.A 52
Dr. Falk Pharma GmbH 53
Effimune S.A. 54
Eli Lilly and Company 55
Enceladus Pharmaceuticals BV 56
enGene, Inc 57
Enterome Bioscience SA 58
Epirus Biopharmaceuticals, Inc. 59
Flexion Therapeutics, Inc. 60
Genentech, Inc. 61
Genor BioPharma Co., Ltd. 62
Gilead Sciences, Inc. 63
GlaxoSmithKline Plc 64
GW Pharmaceuticals Plc 65
iCo Therapeutics Inc. 66
Idera Pharmaceuticals, Inc. 67
InDex Pharmaceuticals AB 68
Innovate Biopharmaceuticals, Inc. 69
INOXIA Lifesciences GmbH 70
Intas Pharmaceuticals Ltd. 71
Invion Limited 72
Johnson & Johnson 73
Kaken Pharmaceutical Co., Ltd. 74
Kymab Limited 75
Kyowa Hakko Kirin Co., Ltd. 76
LIPID THERAPEUTICS GmbH 77
Mabion SA 78
Medestea Research & Production S.p.A. 79
Mitsubishi Tanabe Pharma Corporation 80
Momenta Pharmaceuticals, Inc. 81
Morphotek, Inc. 82
Mycenax Biotech Inc. 83
Oncobiologics, Inc. 84
Pfizer Inc. 85
Pluristem Therapeutics Inc. 86
ProtAb Ltd 87
Protagonist Therapeutics Inc. 88
Qu Biologics Inc. 89
Re-Pharm Limited 90
Rebiotix Inc. 91
Sandoz International GmbH 92
Seres Therapeutics, Inc. 93
Sigmoid Pharma Limited 94
Stelic Institute & Co., Inc. 95
sterna biologicals Gmbh & Co KG 96
Synergy Pharmaceuticals, Inc. 97
Takeda Pharmaceutical Company Limited 98
Therapeutic Proteins International, LLC 99
Therapix Biosciences Ltd 100
Theravance Biopharma, Inc. 101
Tillotts Pharma AG 102
Trino Therapeutics Limited 103
Ventria Bioscience 104
Ulcerative Colitis - Therapeutics Assessment 105
Assessment by Monotherapy Products 105
Assessment by Target 106
Assessment by Mechanism of Action 110
Assessment by Route of Administration 113
Assessment by Molecule Type 115
Drug Profiles 117
ABS-11 - Drug Profile 117
adalimumab biosimilar - Drug Profile 118
adalimumab biosimilar - Drug Profile 120
adalimumab biosimilar - Drug Profile 121
adalimumab biosimilar - Drug Profile 122
adalimumab biosimilar - Drug Profile 123
adalimumab biosimilar - Drug Profile 124
adalimumab biosimilar - Drug Profile 125
adalimumab biosimilar - Drug Profile 126
AKP-11 - Drug Profile 127
amiselimod hydrochloride - Drug Profile 129
Anatabine - Drug Profile 131
Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug Profile 133
AVX-470 - Drug Profile 134
AW/EPO-002 - Drug Profile 136
AW/EPO-003 - Drug Profile 137
AW/EPOPD-01 - Drug Profile 138
AW/EPOPD-02 - Drug Profile 139
AW/EPOPD-06 - Drug Profile 140
brilacidin tetrahydrochloride - Drug Profile 141
CCX-507 - Drug Profile 143
CKD-506 - Drug Profile 144
D-9030 - Drug Profile 145
dolcanatide - Drug Profile 146
Drug to Inhibit Calpain-2 for Crohn’s Diseases and Ulcerative Colitis - Drug Profile 147
EFFI-7H - Drug Profile 148
EG-10 - Drug Profile 149
EG-12 - Drug Profile 150
enalaprilat - Drug Profile 151
golimumab biosimilar - Drug Profile 152
golimumab biosimilar - Drug Profile 153
golimumab biosimilar - Drug Profile 154
GSK-2982772 - Drug Profile 155
hyaluronate sodium - Drug Profile 156
IAC VITA - Drug Profile 157
IMO-9200 - Drug Profile 159
infliximab biosimilar - Drug Profile 160
infliximab biosimilar - Drug Profile 161
infliximab biosimilar - Drug Profile 162
infliximab biosimilar - Drug Profile 163
INN-108 - Drug Profile 164
INV-88 - Drug Profile 165
KANAb-071 - Drug Profile 166
kPPF-1 - Drug Profile 167
KY-1006 - Drug Profile 168
lipidated tacrolimus - Drug Profile 169
Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn’s Disease - Drug Profile 170
NRG-4 - Drug Profile 171
ozanimod hydrochloride - Drug Profile 173
P-Dex - Drug Profile 175
PH-44 - Drug Profile 177
PH-46A - Drug Profile 178
PH-5 - Drug Profile 179
PNQ-201 - Drug Profile 180
Prozumab - Drug Profile 181
PTG-100 - Drug Profile 182
ranibizumab biosimilar - Drug Profile 184
RBX-2660 - Drug Profile 185
RBX-8225 - Drug Profile 187
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 188
Rosburix - Drug Profile 190
SER-287 - Drug Profile 191
SER-301 - Drug Profile 192
Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile 193
Small Molecule to Scavenge Nitric Oxide Radical for Ulcerative Colitis and Inflammation - Drug Profile 194
Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 195
Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 196
TAK-114 - Drug Profile 197
TD-1473 - Drug Profile 199
TOP-1288 - Drug Profile 200
TP-10 - Drug Profile 201
VEN-120 - Drug Profile 202
Ulcerative Colitis - Recent Pipeline Updates 203
Ulcerative Colitis - Dormant Projects 234
Ulcerative Colitis - Discontinued Products 243
Ulcerative Colitis - Product Development Milestones 245
Featured News & Press Releases 245
Appendix 254
Methodology 254
Coverage 254
Secondary Research 254
Primary Research 254
Expert Panel Validation 254
Contact Us 254
Disclaimer 255
List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2016 17
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 20
Number of Products under Development by Companies, H1 2016 (Contd..1) 21
Number of Products under Development by Companies, H1 2016 (Contd..2) 22
Number of Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Development by Companies, H1 2016 (Contd..4) 24
Number of Products under Development by Companies, H1 2016 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Development, H1 2016 29
Comparative Analysis by Unknown Stage Development, H1 2016 30
Products under Development by Companies, H1 2016 31
Products under Development by Companies, H1 2016 (Contd..1) 32
Products under Development by Companies, H1 2016 (Contd..2) 33
Products under Development by Companies, H1 2016 (Contd..3) 34
Products under Development by Companies, H1 2016 (Contd..4) 35
Products under Development by Companies, H1 2016 (Contd..5) 36
Products under Development by Companies, H1 2016 (Contd..6) 37
Products under Development by Companies, H1 2016 (Contd..7) 38
Products under Investigation by Universities/Institutes, H1 2016 39
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H1 2016 40
Ulcerative Colitis - Pipeline by AbbVie Inc., H1 2016 41
Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd., H1 2016 42
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2016 43
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2016 44
Ulcerative Colitis - Pipeline by Amgen Inc., H1 2016 45
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 46
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H1 2016 47
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2016 48
Ulcerative Colitis - Pipeline by BioAtla, LLC, H1 2016 49
Ulcerative Colitis - Pipeline by Bionovis SA, H1 2016 50
Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2016 51
Ulcerative Colitis - Pipeline by Cellceutix Corporation, H1 2016 52
Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H1 2016 53
Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2016 54
Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 55
Ulcerative Colitis - Pipeline by Coherus BioSciences, Inc., H1 2016 56
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016 57
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 58
Ulcerative Colitis - Pipeline by Effimune S.A., H1 2016 59
Ulcerative Colitis - Pipeline by Eli Lilly and Company, H1 2016 60
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2016 61
Ulcerative Colitis - Pipeline by enGene, Inc, H1 2016 62
Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H1 2016 63
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 64
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2016 65
Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2016 66
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 67
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2016 68
Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H1 2016 69
Ulcerative Colitis - Pipeline by GW Pharmaceuticals Plc, H1 2016 70
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2016 71
Ulcerative Colitis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 72
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2016 73
Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016 74
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2016 75
Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 76
Ulcerative Colitis - Pipeline by Invion Limited, H1 2016 77
Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2016 78
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 79
Ulcerative Colitis - Pipeline by Kymab Limited, H1 2016 80
Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 81
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2016 82
Ulcerative Colitis - Pipeline by Mabion SA, H1 2016 83
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2016 84
Ulcerative Colitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 85
Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 86
Ulcerative Colitis - Pipeline by Morphotek, Inc., H1 2016 87
Ulcerative Colitis - Pipeline by Mycenax Biotech Inc., H1 2016 88
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2016 89
Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2016 90
Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H1 2016 91
Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2016 92
Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc., H1 2016 93
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2016 94
Ulcerative Colitis - Pipeline by Re-Pharm Limited, H1 2016 95
Ulcerative Colitis - Pipeline by Rebiotix Inc., H1 2016 96
Ulcerative Colitis - Pipeline by Sandoz International GmbH, H1 2016 97
Ulcerative Colitis - Pipeline by Seres Therapeutics, Inc., H1 2016 98
Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H1 2016 99
Ulcerative Colitis - Pipeline by Stelic Institute & Co., Inc., H1 2016 100
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 101
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 102
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 103
Ulcerative Colitis - Pipeline by Therapeutic Proteins International, LLC, H1 2016 104
Ulcerative Colitis - Pipeline by Therapix Biosciences Ltd, H1 2016 105
Ulcerative Colitis - Pipeline by Theravance Biopharma, Inc., H1 2016 106
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2016 107
Ulcerative Colitis - Pipeline by Trino Therapeutics Limited, H1 2016 108
Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2016 109
Assessment by Monotherapy Products, H1 2016 110
Number of Products by Stage and Target, H1 2016 112
Number of Products by Stage and Mechanism of Action, H1 2016 116
Number of Products by Stage and Route of Administration, H1 2016 119
Number of Products by Stage and Molecule Type, H1 2016 121
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2016 208
Ulcerative Colitis - Dormant Projects, H1 2016 239
Ulcerative Colitis - Dormant Projects (Contd..1), H1 2016 240
Ulcerative Colitis - Dormant Projects (Contd..2), H1 2016 241
Ulcerative Colitis - Dormant Projects (Contd..3), H1 2016 242
Ulcerative Colitis - Dormant Projects (Contd..4), H1 2016 243
Ulcerative Colitis - Dormant Projects (Contd..5), H1 2016 244
Ulcerative Colitis - Dormant Projects (Contd..6), H1 2016 245
Ulcerative Colitis - Dormant Projects (Contd..7), H1 2016 246
Ulcerative Colitis - Dormant Projects (Contd..8), H1 2016 247
Ulcerative Colitis - Discontinued Products, H1 2016 248
Ulcerative Colitis - Discontinued Products (Contd..1), H1 2016 249
List of Figures
Number of Products under Development for Ulcerative Colitis, H1 2016 17
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Products, H1 2016 29
Assessment by Monotherapy Products, H1 2016 110
Number of Products by Top 10 Targets, H1 2016 111
Number of Products by Stage and Top 10 Targets, H1 2016 111
Number of Products by Top 10 Mechanism of Actions, H1 2016 115
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 115
Number of Products by Top 10 Routes of Administration, H1 2016 118
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 118
Number of Products by Top 10 Molecule Types, H1 2016 120
Number of Products by Stage and Top 10 Molecule Types, H1 2016 120
